Background: Glucocorticoids (GCs) are the cornerstone of polymyalgia rheumatica (PMR)
therapy, but their long-term use (as is usually necessary in PMR patients) can induce many …

… treatment target, distinct from the clinical one, as part of a dual-target approach with
personalized… steroid sparing agent in the treatment of polymyalgia rheumatica and giant cell …

… conducted for publications on ‘polymyalgia rheumatica’ AND ‘relapses’ AND ‘risk factors’. …
a steroid sparing agent in the treatment of polymyalgia rheumatica and giant cell arteritis? Ann …

… to specialist settings would improve disease stratification and personalized treatment … Can
methotrexate be used as a steroid sparing agent in the treatment of polymyalgia rheumatica …

… Further research on pathophysiology is required to gain a deeper understanding of the
underlying processes, which will serve as the foundation for future personalized treatments. In …

… Current data concerning the effect of biological treatments in polymyalgia rheumatica are
few and disparate. Studies evaluating anti-TNF agents have not demonstrated sufficient …

… The effectiveness of methotrexate as a corticosteroid-sparing treatment in early polymyalgia
rheumatica is demonstrated, although modest, in the two randomized, blinded, placebo-…

Background Polymyalgia rheumatica (PMR) is a common inflammatory disease in elderly
persons whose mechanism of pathogenesis has not been elucidated. Glucocorticoids are the …

… Polymyalgia rheumatica (PMR) is an inflammatory disease of unknown aetiology affecting
people over 50. With a lifetime risk of 2.4% for women and 1.7% for men, it is one of the most …

… In order to personalize treatment, it would be desirable to stratify patients according to disease
severity, comorbidities and risk of developing GC-related toxicities. Unfortunately, data on …